Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 371 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hemodialysis treatment Clear all
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Behavioral Management of Phosphorus in Hemodialysis Patients

NCT02940743
View directory record Official record
Conditions
Cardiovascular Disease (CKD), Hyperphosphatemia
Interventions
Education (Edu), SM intervention, Social Cognitive Therapy (SCT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 11, 2026, 11:41 PM EDT
Terminated Not applicable Interventional Results available

Interventions Made to Preserve Cognitive Function

NCT03616535
View directory record Official record
Conditions
ESRD
Interventions
Cognitive training, Exercise training, Combined cognitive and exercise training
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

NCT03108924
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Gefapixant
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 11, 2026, 11:41 PM EDT
Completed No phase listed Observational

Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis

NCT00583973
View directory record Official record
Conditions
Hemodialysis, Chronic Kidney Disease, Inflammation
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 11, 2026, 11:41 PM EDT
Not listed No phase listed Observational

Evaluation of the Optimal Transition Program

NCT04263233
View directory record Official record
Conditions
ESRD, Hemodialysis
Interventions
Analysis using descriptive statistics of patient clinical outcomes., Surveys with participants using validated survey tools., Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Oakland, California • Sacramento, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

The Merit WRAPSODY AV Access Efficacy Study (WAVE)

NCT04540302
View directory record Official record
Conditions
Venous Stenosis, Venous Occlusion
Interventions
Merit WRAPSODY Endovascular Stent Graft, PTA
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
33
States / cities
Tempe, Arizona • Tucson, Arizona • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Palm Tocotrienols in Chronic Hemodialysis (USA)

NCT02358967
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
TRF (Tocotrienol-rich-fraction), Placebo
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Identifying and Treating Depression in Hemodialysis Patients

NCT03390933
View directory record Official record
Conditions
Depression, Hemodialysis-Induced Symptom
Interventions
Fluoxetine
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 11, 2026, 11:41 PM EDT
Recruiting No phase listed Observational

Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

NCT06533254
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Predicting choice of dialysis, Behavioral nudges
Other · Behavioral
Lead sponsor
Scaled Insights
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Iron Indices and Intravenous Ferumoxytol: Time to Steady State

NCT01148745
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol
Drug
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Immune Effects of Vitamin D in Hemodialysis Patients

NCT00686751
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions
paricalcitol
Drug
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 11, 2026, 11:41 PM EDT
Completed No phase listed Observational

A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients

NCT02320513
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Wearing activty monitoring device (Fitbit Flex), Fitbit Flex
Other · Device
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 11, 2026, 11:41 PM EDT
Completed No phase listed Observational

Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years

NCT00874380
View directory record Official record
Conditions
Cardiovascular Outcome, Kalemia Control, Lipid Profile
Interventions
Increasing total fiber intake in patient's diet
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 11, 2026, 11:41 PM EDT
Recruiting Phase 3 Interventional

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

NCT05834777
View directory record Official record
Conditions
Intradialytic Hypotension
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 11, 2026, 11:41 PM EDT
Suspended Not applicable Interventional

The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I

NCT04898010
View directory record Official record
Conditions
Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Motivational Strategies To Empower African Americans To Improve Dialysis Adherence

NCT05003115
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Motivational interviewing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

NCT04933747
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Iberdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Orlando, Florida • Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Dietary Protein Requirements in Hemodialysis Patients

NCT02194114
View directory record Official record
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 11, 2026, 11:41 PM EDT
Active, not recruiting Phase 3 Interventional

Vafseo Outcomes In-Center Experience

NCT06520826
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Vadadustat, Erythropoiesis Stimulating Agent
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 11, 2026, 11:41 PM EDT
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Choice Sets for Advance Directives

NCT02209038
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded AD Choice, Expanded Life-sustaining Therapy Choice
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Camden, New Jersey • Philadelphia, Pennsylvania • Radnor, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 11, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 11, 2026, 11:41 PM EDT